A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if a flexible dose of Symbicort has a similar effect on the airways of patients with asthma as a higher fixed-dose of Symbicort with additional glucocorticosteroids added.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Formoterol Fumarate; Terbutaline

Criteria

Inclusion Criteria:

• Diagnosis of asthma for at least 6 months

• Prescribed daily use of glucocorticosteroids for at least 3 months prior to visit one

Exclusion Criteria:

• Respiratory infection affecting asthma within 30 days prior to study

• Intake of oral, rectal, or parenteral glucocorticosteroids within 30 days prior to study

• Any significant disease or disorder that may jeopardize the safety of the patient